@article{71a918100a88453e83c4f7ed875a53e9,
title = "Use and interpretation of diagnostic vaccination in primary immunodeficiency: A working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology",
abstract = "A major diagnostic intervention in the consideration of many patients suspected to have primary immunodeficiency diseases (PIDDs) is the application and interpretation of vaccination. Specifically, the antibody response to antigenic challenge with vaccines can provide substantive insight into the status of human immune function. There are numerous vaccines that are commonly used in healthy individuals, as well as others that are available for specialized applications. Both can potentially be used to facilitate consideration of PIDD. However, the application of vaccines and interpretation of antibody responses in this context are complex. These rely on consideration of numerous existing specific studies, interpolation of data from healthy populations, current diagnostic guidelines, and expert subspecialist practice. This document represents an attempt of a working group of the American Academy of Allergy, Asthma & Immunology to provide further guidance and synthesis in this use of vaccination for diagnostic purposes in consideration of PIDD, as well as to identify key areas for further research.",
keywords = "Vaccines, antibody deficiency, antigen challenge, common variable immunodeficiency, diagnosis, guideline, neoantigen, primary immunodeficiency, specific antibody deficiency",
author = "Orange, {Jordan S.} and Mark Ballow and Stiehm, {E. Richard} and Ballas, {Zuhair K.} and Javier Chinen and {De La Morena}, Maite and Dinakantha Kumararatne and Harville, {Terry O.} and Paul Hesterberg and Majed Koleilat and Sean McGhee and Perez, {Elena E.} and Jason Raasch and Rebecca Scherzer and Harry Schroeder and Christine Seroogy and Aarnoud Huissoon and Sorensen, {Ricardo U.} and Rohit Katial",
note = "Funding Information: Publication of this article was supported by CSL Behring . Funding Information: Disclosure of potential conflict of interest: J. S. Orange has received consultancy fees from Baxter Bioscience, Grifols, Octapharma USA, CSL Behring, IBT Reference Laboratories, and Cangene; has received lecture fees from Baxter Bioscience; and receives royalties from UpToDate. M. Ballow has received consulting fees from Baxter, CSL Behring, Grifols; has received fees for participation in review activities from Green Cross DSMB; has received legal fees to review a case; has received lecture fees from Baxter, CSL Behring, and the ACAAI; and has received payment for manuscript preparation from Baxter. E. R. Stiehm has received consultancy fees from UpToDate; is employed by Vela; has provided expert witness testimony on the topic of vaccine adverse effects; has received an unrestricted donation to Dr. Roger Kobayashi Allergy and Immunology Associates of Omaha for travel expenses; and has received travel expenses from the US Immune Deficiency Foundation and March of Dimes. Z. K. Ballas has received research support from Talecris , VA, and the National Institutes of Health (NIH) ; receives royalties from UpToDate; and has served as a member of the AAAAI Board of Directors. M. De La Morena has received research support from the Jeffrey Modell Foundation . D. Kumararatne has received research support from NIHR , UK; has received consultancy fees from Viropharma; has received lecture payments from Baxter; and has received travel funds from CSL Behring . S. McGhee has received lecture fees from Baxter. E. E. Perez has received consultancy fees from Baxter and CSL Behring; is employed by the University of South Florida; and has received payment for the development of educational presentations from Baxter. J. Raasch has received lecture fees from Baxter and CSL Behring and has received payment for the development of educational presentations from Baxter. H. Schroeder has received research support from the NIAID, NABI Pharmaceuticals, and Green Cross Pharmaceuticals ; has received lecture fees from the AAAAI and NABI Pharmaceuticals; and has received royalties from Elsevier as the editor of Clinical Immunology: Principles and Practices. C. Seroogy has received consultancy fees from UpToDate; is employed by the University of Wisconsin; and has received research support from Midwest Athletes Against Childhood Cancer and the NIH . A. Huissoon has served on the Advisory Boards for Biotest, Shire, Swedish Orphan Biovitrum, and Meda; has received lecture fees from GlaxoSmithKline; holds shares in GlaxoSmithKline; has received travel expenses from CSL Behring; and has organized meetings that have been funded by The Binding Site, Ltd . The rest of the authors have declared that they have no relevant conflicts of interest. ",
year = "2012",
month = sep,
doi = "10.1016/j.jaci.2012.07.002",
language = "English (US)",
volume = "130",
pages = "S1--S24",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "3 SUPPL.",
}